CNS & Neurological Disorders - Drug Targets
Formerly: Current Drug Targets - CNS & Neurological Disorders
Volume 19, 10 Issues, 2020
ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)
This journal supports open access
ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)
This journal supports open access
Ranking and Category
-
150th of 267 in
Neurosciences
-
119th of 267 in
Pharmacology & Pharmacy
In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research
Contents
CNS & Neurological Disorders - Drug Targets , Volume 11 - Number 3
Catechol-O-Methyl Transferase Modulates Cognition in Late Life: Evidence and Implications for Cognitive Enhancement
, 11(3): 195 - 208Fabio Sambataro, Maria Pennuto and Robert Christian Wolf
DOI: 10.2174/187152712800672463
COMT as a Drug Target for Cognitive Functions and Dysfunctions
, 11(3): 209 - 221Diego Scheggia, Sara Sannino, Maria Luisa Scattoni and Francesco Papaleo
DOI: 10.2174/187152712800672481
Janus Molecule I: Dichotomous Effects of COMT in Neuropathic vs Nociceptive Pain Modalities
, 11(3): 222 - 235S. K. Segall, W. Maixner, I. Belfer, T. Wiltshire, Z. Seltzer and L. Diatchenko
DOI: 10.2174/187152712800672490
The Role of the Catechol-O-Methyltransferase (COMT) Gene in Personality and Related Psychopathological Disorders
, 11(3): 236 - 250Christian Montag, Magdalena Jurkiewicz and Martin Reuter
DOI: 10.2174/187152712800672382
Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment
, 11(3): 251 - 263Stefano Espinoza, Francesca Manago, Damiana Leo, Tatyana D. Sotnikova and Raul R. Gainetdinov
DOI: 10.2174/187152712800672436
COMT Implication in Cognitive and Psychiatric Symptoms in Chromosome 22q11 Microdeletion Syndrome: A Selective Review
, 11(3): 273 - 281Marco Armando, Francesco Papaleo and Stefano Vicari
DOI: 10.2174/187152712800672526
Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia
, 11(3): 282 - 291Colm M.P. O’Tuathaigh, Lieve Desbonnet, Peter Lee and John L. Waddington
DOI: 10.2174/187152712800672418
Current Understanding of the Interplay Between Catechol-OMethyltransferase Genetic Variants, Sleep, Brain Development and Cognitive Performance in Schizophrenia
, 11(3): 292 - 298Valter Tucci, Glenda Lassi and Martien J. Kas
DOI: 10.2174/187152712800672454
Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings
, 11(3): 299 - 305Alessandro Serretti and Paolo Olgiati
DOI: 10.2174/187152712800672472
The Role of Catechol-O-Methyltransferase in Reward Processing and Addiction
, 11(3): 306 - 323E. M. Tunbridge, A. Huber, S. M. Farrell, K. Stumpenhorst, P. J. Harrison and M. E. Walton
DOI: 10.2174/187152712800672409
Inhibitors of Catechol-O-Methyltransferase
, 11(3): 324 - 332James C. Barrow
DOI: 10.2174/187152712800672517
Editor-in-Chief
Edoardo Spina
Department of Clinical and Experimental Medicine
University of Messina
Policlinico Universitario
Via Consolare Valeria
Messina
(Italy)
Biography
Department of Clinical and Experimental Medicine
University of Messina
Policlinico Universitario
Via Consolare Valeria
Messina
Biography
Biography of Edoardo Spina
Dr. Spina graduated in Medicine, specialized in Neurology and in Psychiatry at the University of Messina, Italy. He obtained a doctorate (Ph.D) in Clinical Pharmacology at Karolinska Institute, Stockholm. Currently, Dr. Spina is Professor of Pharmacology at the Department of Clinical and Experimental Medicine, University of Messina. His main scientific interest is clinical neuropsychopharmacology. Dr. Spina authored more than 200 articles in international journals and 2 books. He is Associate Editor of Frontiers in Pharmacogenetics and member of the editorial board of Therapeutic Drug Monitoring, Basic & Clinical Pharmacology & Toxicology and Neuropsychiatric Disease and Treatment.
COPE Compliant
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Drug Targets - CNS & Neurological Disorders was launched in 2002 and later renamed in 2006 as CNS & Neurological Disorders - Drug Targets.
Scopus CiteScore Metrics: 2.72
Advertisement
Webmaster Contact: info@benthamscience.net